자폐증 선별 및 진단 툴 시장 예측(-2034년) - 툴 유형, 비즈니스 모델, 제공 형태, 최종사용자, 지역별 분석

According to Stratistics MRC, the Global Autism Screening and Diagnostic Tools Market is accounted for $0.5 billion in 2026 and is expected to reach $0.7 billion by 2034 growing at a CAGR of 3.8% during the forecast period. Autism screening and diagnostic instruments play a crucial role in detecting and evaluating autism spectrum disorder (ASD) at various stages of life. Initial screening methods, including structured questionnaires and observation checklists, help identify individuals who may need detailed assessment. Diagnostic tools involve in-depth evaluations by qualified specialists, focusing on behavior, communication skills, social interactions, and developmental history. Accurate and early diagnosis supports prompt intervention, which can significantly improve overall outcomes and daily functioning. With ongoing technological advancements, these tools are becoming more accessible, efficient, and consistent, allowing broader use in healthcare systems and community environments worldwide.

According to the CDC and NIMH, autism prevalence data shows that about 1 in 31 children (3.2%) aged 8 years were identified with Autism Spectrum Disorder (ASD) in 2022 across 16 U.S. communities, with boys being 3.4 times more likely than girls to be diagnosed.

Market Dynamics:

Driver:

Rising prevalence of autism spectrum disorder (ASD)

The growing incidence of autism spectrum disorder (ASD) worldwide is significantly boosting the demand for screening and diagnostic tools. Heightened awareness among caregivers, teachers, and medical professionals has resulted in more individuals undergoing evaluation. Broader diagnostic guidelines and better data tracking have also led to increased identification rates. As diagnoses become more common, there is a greater need for reliable and efficient assessment tools. This rising demand is prompting healthcare providers to integrate advanced diagnostic technologies that enable early detection and timely intervention, helping improve long-term developmental outcomes and quality of life for individuals with autism.

Restraint:

High cost of diagnostic tools and services

Expensive autism screening and diagnostic services present a major challenge to market growth. Detailed evaluations typically involve skilled specialists, repeated assessments, and sophisticated technologies, increasing overall costs. In developing regions, inadequate insurance support and high personal expenses limit access for many individuals. Healthcare providers may also struggle to invest in advanced tools due to financial limitations. These cost barriers often lead to delayed diagnoses and reduced utilization of diagnostic services. Overcoming affordability challenges is crucial to expanding access and ensuring that more individuals benefit from timely autism assessment and appropriate intervention strategies.

Opportunity:

Increased focus on early childhood screening programs

The growing importance of early childhood screening initiatives is creating promising opportunities for the autism diagnostic tools market. Public health agencies and medical institutions are emphasizing early detection to enhance developmental outcomes. Screening programs in educational institutions, clinics, and community centers are increasing tool adoption. Identifying autism at an early stage allows for prompt intervention, which can reduce long-term challenges. This trend is encouraging the development and use of efficient and accessible diagnostic solutions. As these programs expand worldwide, they are expected to boost the demand for autism screening tools and support market growth.

Threat:

Risk of misdiagnosis and diagnostic errors

Diagnostic inaccuracies and the possibility of misidentification pose serious concerns in the autism screening market. The complexity of autism symptoms and similarities with other developmental disorders can lead to incorrect assessments. Errors in diagnosis may result in unsuitable treatments or delays in necessary interventions. Dependence on limited screening techniques without thorough evaluation can worsen the issue. These challenges may reduce confidence in diagnostic tools among professionals and families. Ensuring higher accuracy through validation and comprehensive approaches is essential, as concerns about reliability can hinder the adoption and effectiveness of autism screening technologies.

Covid-19 Impact:

The COVID-19 pandemic influenced the autism screening and diagnostic tools market in both challenging and transformative ways. Early in the crisis, restrictions and interruptions in healthcare services caused delays in assessments and reduced access to diagnostic facilities. Temporary closures of clinics hindered early detection and intervention. At the same time, the situation encouraged the rapid adoption of telehealth and digital solutions, allowing remote evaluations and consultations. These virtual approaches enhanced accessibility and flexibility for patients. Following the pandemic, the market has rebounded, with increased focus on integrating digital technologies alongside traditional in-person diagnostic methods.

The behavioral assessment tools segment is expected to be the largest during the forecast period

The behavioral assessment tools segment is expected to account for the largest market share during the forecast period, mainly because of their strong clinical credibility and extensive usage. They are widely regarded as the primary method for diagnosing autism, as they focus on observing behaviour, communication abilities, and social interactions in a structured manner. Medical professionals prefer these tools due to their proven effectiveness and detailed evaluation approach. Their adaptability across different environments, such as healthcare facilities and educational institutions, strengthens their position. Ongoing improvements and consistent standardization further enhance their reliability, ensuring continued widespread adoption across global healthcare systems.

The parents & caregivers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the parents & caregivers segment is predicted to witness the highest growth rate, driven by heightened awareness and active participation in early identification. Increased availability of digital platforms, mobile apps, and online screening tools enables caregivers to conduct initial assessments at home. The growing focus on early diagnosis and developmental tracking encourages families to adopt accessible solutions. Easy-to-use technologies allow non-experts to recognize early symptoms effectively. This trend toward self-directed screening and home-based evaluation is accelerating the expansion of this segment, making it a key contributor to market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by its well-developed healthcare system and high level of awareness. The region has robust government initiatives, structured diagnostic processes, and easy access to skilled professionals. Early detection programs and supportive reimbursement frameworks encourage the use of diagnostic tools. Moreover, the presence of major industry players and ongoing technological innovations strengthens its leadership. The rising number of autism cases and increasing focus on early intervention further boost market growth, making North America the dominant region in this sector.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by advancements in healthcare systems and growing awareness of developmental conditions. Increased investments and economic progress are enhancing access to diagnostic services in developing countries. Authorities and healthcare organizations are focusing on early detection and intervention programs. The region's large population and unmet medical needs provide significant opportunities for expansion. Moreover, the rising use of digital health platforms and telemedicine is accelerating adoption. These factors collectively position Asia-Pacific as the fastest-growing region in the autism diagnostics market.

Key players in the market

Some of the key players in Autism Screening and Diagnostic Tools Market include Abbott Laboratories, ARUP Laboratories, Bio-Rad Laboratories, Cognoa, Cortica Inc, EarliTec Diagnostics, F. Hoffmann-La Roche Ltd, Fulgent Genetics, Illumina, Invitae, LabCorp, LinusBio, Natera, Pearson Clinical, Qbtech AB, Quest Diagnostics, Siemens Healthineers and Thermo Fisher Scientific.

Key Developments:

In February 2026, Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care for neurodegenerative disease and the management of prostate cancer and metastatic liver tumors. The two organizations have signed an agreement that will improve care for those disease states and expand access to new imaging and interventional technologies.

In November 2025, Abbott and Exact Sciences announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.

In October 2025, Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials. The deal includes potential additional earnout and other payments contingent on future performance. Clario's platform integrates clinical trial endpoint data from devices, sites, and patients, enabling pharmaceutical and biotechnology companies to digitally collect, manage, and analyze clinical evidence across all phases of drug development.

Tool Types Covered:

• Behavioral Assessment Tools
• Developmental Screening Questionnaires
• Neuroimaging & Biomarker-based Diagnostics
• AI-enabled Digital Screening Platforms
• Genetic Testing Kits

Business Models Covered:

• Subscription-based Digital Platforms
• One-time Purchase Kits
• Institutional Licensing
• Hybrid

Delivery Modes Covered:

• In-clinic Screening Tools
• Home-based & Remote Screening Solutions
• School-based Screening Programs
• Telehealth-enabled Diagnostic Platforms

End Users Covered:

• Pediatric Clinics & Hospitals
• Diagnostic Laboratories
• Educational Institutions
• Research Centers
• Parents & Caregivers

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Autism Screening and Diagnostic Tools Market, By Tool Type

• 5.1 Behavioral Assessment Tools
• 5.2 Developmental Screening Questionnaires
• 5.3 Neuroimaging & Biomarker-based Diagnostics
• 5.4 AI-enabled Digital Screening Platforms
• 5.5 Genetic Testing Kits

6 Global Autism Screening and Diagnostic Tools Market, By Business Model

• 6.1 Subscription-based Digital Platforms
• 6.2 One-time Purchase Kits
• 6.3 Institutional Licensing
• 6.4 Hybrid

7 Global Autism Screening and Diagnostic Tools Market, By Delivery Mode

• 7.1 In-clinic Screening Tools
• 7.2 Home-based & Remote Screening Solutions
• 7.3 School-based Screening Programs
• 7.4 Telehealth-enabled Diagnostic Platforms

8 Global Autism Screening and Diagnostic Tools Market, By End User

• 8.1 Pediatric Clinics & Hospitals
• 8.2 Diagnostic Laboratories
• 8.3 Educational Institutions
• 8.4 Research Centers
• 8.5 Parents & Caregivers

9 Global Autism Screening and Diagnostic Tools Market, By Geography

• 9.1 North America
  • 9.1.1 United States
  • 9.1.2 Canada
  • 9.1.3 Mexico
• 9.2 Europe
  • 9.2.1 United Kingdom
  • 9.2.2 Germany
  • 9.2.3 France
  • 9.2.4 Italy
  • 9.2.5 Spain
  • 9.2.6 Netherlands
  • 9.2.7 Belgium
  • 9.2.8 Sweden
  • 9.2.9 Switzerland
  • 9.2.10 Poland
  • 9.2.11 Rest of Europe
• 9.3 Asia Pacific
  • 9.3.1 China
  • 9.3.2 Japan
  • 9.3.3 India
  • 9.3.4 South Korea
  • 9.3.5 Australia
  • 9.3.6 Indonesia
  • 9.3.7 Thailand
  • 9.3.8 Malaysia
  • 9.3.9 Singapore
  • 9.3.10 Vietnam
  • 9.3.11 Rest of Asia Pacific
• 9.4 South America
  • 9.4.1 Brazil
  • 9.4.2 Argentina
  • 9.4.3 Colombia
  • 9.4.4 Chile
  • 9.4.5 Peru
  • 9.4.6 Rest of South America
• 9.5 Rest of the World (RoW)
  • 9.5.1 Middle East
    • 9.5.1.1 Saudi Arabia
    • 9.5.1.2 United Arab Emirates
    • 9.5.1.3 Qatar
    • 9.5.1.4 Israel
    • 9.5.1.5 Rest of Middle East
  • 9.5.2 Africa
    • 9.5.2.1 South Africa
    • 9.5.2.2 Egypt
    • 9.5.2.3 Morocco
    • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

• 10.1 Industry Value Network and Supply Chain Assessment
• 10.2 White-Space and Opportunity Mapping
• 10.3 Product Evolution and Market Life Cycle Analysis
• 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

• 11.1 Mergers and Acquisitions
• 11.2 Partnerships, Alliances, and Joint Ventures
• 11.3 New Product Launches and Certifications
• 11.4 Capacity Expansion and Investments
• 11.5 Other Strategic Initiatives

12 Company Profiles

• 12.1 Abbott Laboratories
• 12.2 ARUP Laboratories
• 12.3 Bio-Rad Laboratories
• 12.4 Cognoa
• 12.5 Cortica Inc
• 12.6 EarliTec Diagnostics
• 12.7 F. Hoffmann-La Roche Ltd
• 12.8 Fulgent Genetics
• 12.9 Illumina
• 12.10 Invitae
• 12.11 LabCorp
• 12.12 LinusBio
• 12.13 Natera
• 12.14 Pearson Clinical
• 12.15 Qbtech AB
• 12.16 Quest Diagnostics
• 12.17 Siemens Healthineers
• 12.18 Thermo Fisher Scientific